The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
 
Rodabe Amaria
Consulting or Advisory Role - Erasca, Inc; IO Biotech; KSQ Therapeutics; Obsidian Therapeutics; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Erasc (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst); Regeneron (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis
 
Maria Pia Morelli
No Relationships to Disclose
 
George Blumenschein
Employment - Janssen (I); johnon & Johnson (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Clovis Oncology; CytomX Therapeutics; Daiichi Sankyo, INC; Genentech; Genzyme; Gilead Sciences; Immunocore; Instil Bio; InterVenn Biosciences; Janssen Oncology; Johnson & Johnson (I); Lilly; Maverick Therapeutics; MedImmune; Merck; Novartis; Onconova Therapeutics; Regeneron; Roche; Sanofi; Scorpion Therapeutics; Seagen; Tyme; Virogin Biotech; Xcovery
Research Funding - Adaptimmune; Amgen; AstraZeneca; Aulos Bioscience; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; CytomX Therapeutics; Daiichi Sankyo INC; Duality Biologics; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Medimmune; Merck; Merck; Mythic Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Repertoire Immune Medicines; Roche; Sanofi; seagen; Takeda; Tmunity Therapeutics, Inc.; Torque; Turning Point Therapeutics; Verastem; Xcovery
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline; InSightec; Lyell Immunopharma; Regeneron
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst); verismo (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - Hengenix; Nanobiotix (Inst)
 
Khaled Sanber
No Relationships to Disclose
 
Amir Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Premier Research
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Global; Iovance Biotherapeutics; Macrogenics; Sentinel Bio; Theolytics
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); GlaxoSmithKline (Inst); immatics (Inst); Imunon (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Stryker
 
Michael Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Nurix; Pfizer; Replimune
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Adi Diab
Honoraria - Cullinan Oncology (Inst); CureVac; CytomX Therapeutics; Genesis Therapeutics; Idera (Inst); Lytix Biopharma (Inst); Memgen; Nektar (Inst); Pfizer; Regeneron; Teva
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Cullinan Oncology (Inst); Cullinan Oncology (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
 
Isabella Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Jennifer McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
Chantale Bernatchez
No Relationships to Disclose
 
Marie-Andree Forget
No Relationships to Disclose
 
Cara Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Regeneron
Research Funding - Avenge Bio (Inst); BTG (Inst); Dragonfly Therapeutics (Inst); Iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst); Yingli Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Karrie Wong
Employment - KSQ Therapeutics
 
Erica Tobin
Employment - KSQ Therapeutics
 
Micah Benson
Employment - KSQ Therapeutics
 
Anna Truppel-Hartmann
Employment - KSQ Therapeutics